Today, February 29, 2024 Taysha Gene Therapies provided some updates for all their clinical trials (Canada, US, UK). Here is a summary of the updates:
- The REVEAL Adolescent & Adult Study (females age 12+) will expand into the US following submission of an investigational new drug application to the FDA.
- The REVEAL Adolescent & Adult Study will proceed to the next dose cohort (or “group”) following approval from the study’s Independent Data Monitoring Committee (IDMC) to move to the next dose level. Dosing of the first participant in cohort two (high dose) is expected in Q2 2024.
- The IDMC also approved the dosing of the second participant in cohort one (low dose) of the REVEAL Pediatric Study, which is expected to take place in Q1 2024.
Please explore the links below for additional details.